Download Free Health Care Technology And Its Assessment In Eight Countries Book in PDF and EPUB Free Download. You can read online Health Care Technology And Its Assessment In Eight Countries and write the review.

This background paper is part of a larger study on International Differences in Health Care Technology and Spending, which consists of a series of back- ground papers. International Health Statistics: What the numbers mean for the United States was published in November 1993, and International Comparisons of Administrative Costs in Health Care appeared in September 1994. An additional background paper will report on lessons for the United States from a comparison; of hospital financing and spending in seven countries.
Examines the management of health care technology in 8 countries: Australia, Canada, France, Germany, the Netherlands, Sweden, the U.K & the U.S. Six technologies (or sets of technologies) -- including evaluation & management efforts & how the technologies diffused -- are presented & compared: treatments for coronary artery disease, imaging technologies (CT & MRI scanning), laparoscopic surgery, treatments for end-stage renal disease, neonatal intensive care, & breast cancer screening. Extensive bibliography for each country. Charts & tables.
This book disentangles the issues in connection with the advancement of Health Technology Assessment (HTA) and its interface with health policy. It highlights the factors that should shape its progress in the near future. Interdisciplinary and critical views from a number of professionals are put together in a prescient order to cast some light and make recommendations as to the next steps HTA should take to be fit for purpose. A wealth of documents dealing with HTA have been published over the last three decades. HTA allegedly is one of the bedrocks of regulation and medical decision making. However, counter vailing visions contend that geographical variations in the role that HTA is actually playing within countries pinpoints specific room for improvement. Given our social preferences, cherry-picking HTA’s features and successes over the last decades moves it away from its possibility frontier. Some of the most noteworthy hindrances that HTA faces, in several countries, to making headway towards its consolidation as an efficient tool for regulation and decision making are as follows: insufficient resources, delays in assessment, inadequate priority setting, regulatory capture, public distrust, actual influence on regulatory decisions, the need for strengthening international cooperation and harmony, the lack of sound and consistent assessments of diagnostic tests, medical devices and surgical innovations and limited dissemination. Time has come for HTA to take a renewed stand. There is a pressing need to submit HTA to in-depth critical scrutiny.
Since 1945, a broad array of health care technologies have come into use, including antibiotics, anti-hypertensive drugs, oral diuretics, oral contraceptives, psycho-pharmaceuticals, corticosteroids, vaccines, open-heart surgery, genetics screening, automated clinical laboratories, renal dialysis, and cardiac pacemakers. Unquestionably, these technologies have brought benefits to millions. However, as costs of health care have risen rapidly, governments have increasingly singled out expensive technology as the culprit. The result has been changes in the methods of paying for health care in most countries to control cost rises. This has led to a slowing of technological change in some countries and increasing necessities to choose in all countries. This timely work describes how technology assessment critically evaluates the benefits, costs, and social implications of technology. The book presents an international perspective on health care technology's development and diffusion, and explains how health care technology can enlighten difficult choices faced by policy-makers, clinicians, and patients.
Market access is the process by which a pharmaceutical company gets its product available on the market after having obtained a marketing authorization from a regulatory agency and by which the product becomes available for all patients for whom it is indicated as per its marketing authorization. It covers a group of activities intended to provide access to the appropriate medicine for the appropriate group of patients at the appropriate price (in most countries). Market Access may also be seen as activities that support the management of potential barriers, such as non-optimal price and reimbursement levels, the restriction of the scope of prescribing for the drug or complicated prescription writing or funding procedures. Since there are cultural differences among countries, any Market Access strategy needs to be culturally sensitive. Pharmaceutical Market Access in emerging markets has been extensively discussed in our previous book, published in 2016. The present book focuses on developed markets with the goal of helping students, academics, industry personnel, government workers, and decision makers understand the environment in developed markets.
Health care and its financing will not be harmonized within the European Union (EU). Therefore, the differences between the health systems of the member-states in a Single European Market are gaining in relevance. The process of economic integration also effects health. This book integrates economics, law, social, political and health sciences in the analysis of health care issues in the EU. It covers the development of health systems and policy in the community, the markets for pharmaceuticals and for medical devices, EU-trends in hospital financing, issues in the comparison of financing systems, especially in the field of private expenditures, reforms of health care financing in social security systems and national health services in the EU and cross-border health care between EU member-states. The results feature an up-to date overview on the European dimension of health care and its financing. The book is relevant to experts in health care organizations, policy, industry and research.
This reader offers instant access to fifty classic and original readings in health policy and management. Compiled by experts, the editors introduce a framework setting out the key policy drivers and policy levers, giving a conceptual framework that provides context for each piece.
A timely work describing how localized hospital-based health technology assessment (HB-HTA) complements general, ‘arms-length’ HTA agency efforts, and what has been the collective global impact of HB-HTA across the globe. While HB-HTA has gained significant momentum over the past few years, expertise in the field, and information on the operation and organization of HB-HTA, has been scattered. This book serves to bring this information together to inform those who are currently working in the field of HTA at the hospital, regional, national or global level. In addition, this book is intended for decision-makers and policy-makers with a stake in determining the uptake and decommissioning of new and established technologies in the hospital setting. HTA has traditionally been performed at the National/Regional level by HTA Agencies, typically linked to governments. Yet hospitals are the main entry door for most health technologies (HTs). Hospital decision-makers must undertake multiple high stakes investment and disinvestment decisions annually for innovative HTs, usually without adequate information. Despite the existence of arms-length HTA Agencies, inadequate information is available to hospital decision-makers either because relevant HTA reports are not yet released at the time of entry of new technologies to the field, or because even when the report exists, the information contained is insufficient to clarify the contextualized informational needs of hospital decision makers. Therefore, there has recently been a rising trend toward hospital-based HTA units and programs. These units/programs complement the work of National/Regional HTA Agencies by providing the key and relevant evidence needed by hospital decision makers in their specific hospital context, and within required decision-making timelines. The emergence of HB-HTA is creating a comprehensive HTA ecosystem across health care levels, which creates better bridges for knowledge translation through relevance and timeliness.